{"id":"https://openalex.org/W7148632306","doi":"https://doi.org/10.1002/ajh.70309","title":"Lenalidomide\u2010Dexamethasone as an Effective and Well\u2010Tolerated Treatment Option for Refractory Rosai\u2010Dorfman\u2010Destombes Disease: A Clinical and Pharmacophenomic Study","display_name":"Lenalidomide\u2010Dexamethasone as an Effective and Well\u2010Tolerated Treatment Option for Refractory Rosai\u2010Dorfman\u2010Destombes Disease: A Clinical and Pharmacophenomic Study","publication_year":2026,"publication_date":"2026-04-02","ids":{"openalex":"https://openalex.org/W7148632306","doi":"https://doi.org/10.1002/ajh.70309","pmid":"https://pubmed.ncbi.nlm.nih.gov/41928050"},"language":"en","primary_location":{"id":"doi:10.1002/ajh.70309","doi":"https://doi.org/10.1002/ajh.70309","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ajh.70309","pdf_url":null,"source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014560486","display_name":"Emily W. Leung","orcid":"https://orcid.org/0000-0001-6593-4865","observed_orcids":["https://orcid.org/0000-0001-6593-4865"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]},{"id":"https://openalex.org/I2802394193","display_name":"Nova Scotia Health Authority","ror":"https://ror.org/035gna214","country_code":"CA","type":"government","lineage":["https://openalex.org/I2802394193"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Emily Leung","raw_affiliation_strings":["Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Innovation Hub  Halifax Nova Scotia Canada","Department of Medicine University of British Columbia  Vancouver British Columbia Canada"],"raw_orcid":"https://orcid.org/0000-0001-6593-4865","affiliations":[{"raw_affiliation_string":"Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Innovation Hub  Halifax Nova Scotia Canada","institution_ids":["https://openalex.org/I2802394193"]},{"raw_affiliation_string":"Department of Medicine University of British Columbia  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054484845","display_name":"Nicholas Ronald Fragola","orcid":"https://orcid.org/0000-0002-3049-6145","observed_orcids":["https://orcid.org/0000-0002-3049-6145"]},"institutions":[{"id":"https://openalex.org/I4405260438","display_name":"Every Cure","ror":"https://ror.org/03rh5w887","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405260438"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas R. Fragola","raw_affiliation_strings":["Every Cure  Philadelphia Pennsylvania USA"],"raw_orcid":"https://orcid.org/0000-0002-3049-6145","affiliations":[{"raw_affiliation_string":"Every Cure  Philadelphia Pennsylvania USA","institution_ids":["https://openalex.org/I4405260438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5128814153","display_name":"Elliott W. Sharp","orcid":"https://orcid.org/0000-0003-2955-4640","observed_orcids":["https://orcid.org/0000-0003-2955-4640"]},"institutions":[{"id":"https://openalex.org/I4405260438","display_name":"Every Cure","ror":"https://ror.org/03rh5w887","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405260438"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elliott W. Sharp","raw_affiliation_strings":["Every Cure  Philadelphia Pennsylvania USA"],"raw_orcid":"https://orcid.org/0000-0003-2955-4640","affiliations":[{"raw_affiliation_string":"Every Cure  Philadelphia Pennsylvania USA","institution_ids":["https://openalex.org/I4405260438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045061146","display_name":"Rebecca Anne Harrison","orcid":"https://orcid.org/0000-0002-5689-8492","observed_orcids":["https://orcid.org/0000-0002-5689-8492"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Rebecca A. Harrison","raw_affiliation_strings":["Division of Medical Oncology, BC Cancer  Vancouver British Columbia Canada","Division of Neurology University of British Columbia  Vancouver British Columbia Canada"],"raw_orcid":"https://orcid.org/0000-0002-5689-8492","affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, BC Cancer  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I1289530486"]},{"raw_affiliation_string":"Division of Neurology University of British Columbia  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002706828","display_name":"Erica A. Peterson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Erica Peterson","raw_affiliation_strings":["Division of Hematology University of British Columbia  Vancouver British Columbia Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology University of British Columbia  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033850519","display_name":"Julia L. Varghese","orcid":"https://orcid.org/0000-0002-4424-634X","observed_orcids":["https://orcid.org/0000-0002-4424-634X"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Julia Varghese","raw_affiliation_strings":["Division of Hematology University of British Columbia  Vancouver British Columbia Canada"],"raw_orcid":"https://orcid.org/0000-0002-4424-634X","affiliations":[{"raw_affiliation_string":"Division of Hematology University of British Columbia  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063843173","display_name":"Shannon C. Jackson","orcid":"https://orcid.org/0000-0003-3603-5988","observed_orcids":["https://orcid.org/0000-0003-3603-5988"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Shannon Jackson","raw_affiliation_strings":["Division of Hematology University of British Columbia  Vancouver British Columbia Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology University of British Columbia  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114235696","display_name":"Xiaotian Julie You","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Xiaotian (Julie) You","raw_affiliation_strings":["Division of Hematology McGill University  Montreal Quebec Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology McGill University  Montreal Quebec Canada","institution_ids":["https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087426972","display_name":"Elysha Vanderveer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Elysha VanderVeer","raw_affiliation_strings":["Division of Hematology British Columbia Cancer Agency  Surrey British Columbia Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology British Columbia Cancer Agency  Surrey British Columbia Canada","institution_ids":["https://openalex.org/I1289530486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029200964","display_name":"Mark Trinder","orcid":"https://orcid.org/0000-0001-8447-2897","observed_orcids":["https://orcid.org/0000-0001-8447-2897"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Mark Trinder","raw_affiliation_strings":["Department of Pathology and Laboratory Medicine University of British Columbia  Vancouver British Columbia Canada"],"raw_orcid":"https://orcid.org/0000-0001-8447-2897","affiliations":[{"raw_affiliation_string":"Department of Pathology and Laboratory Medicine University of British Columbia  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ashley Sutherland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I129902397","display_name":"Dalhousie University","ror":"https://ror.org/01e6qks80","country_code":"CA","type":"education","lineage":["https://openalex.org/I129902397"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Ashley Sutherland","raw_affiliation_strings":["Division of Dermatology Dalhousie University  Halifax Nova Scotia Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Dermatology Dalhousie University  Halifax Nova Scotia Canada","institution_ids":["https://openalex.org/I129902397"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046835137","display_name":"Jan Peter Dutz","orcid":"https://orcid.org/0000-0003-3035-0522","observed_orcids":["https://orcid.org/0000-0003-3035-0522"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Jan Dutz","raw_affiliation_strings":["Department of Dermatology and Skin Sciences University of British Columbia  Vancouver British Columbia Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology and Skin Sciences University of British Columbia  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5139167547","display_name":"Piotr Kaniewski","orcid":"https://orcid.org/0009-0003-6318-2171","observed_orcids":["https://orcid.org/0009-0003-6318-2171"]},"institutions":[{"id":"https://openalex.org/I4405260438","display_name":"Every Cure","ror":"https://ror.org/03rh5w887","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405260438"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Piotr Kaniewski","raw_affiliation_strings":["Every Cure  Philadelphia Pennsylvania USA"],"raw_orcid":"https://orcid.org/0009-0003-6318-2171","affiliations":[{"raw_affiliation_string":"Every Cure  Philadelphia Pennsylvania USA","institution_ids":["https://openalex.org/I4405260438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006923130","display_name":"Kenneth L. McClain","orcid":"https://orcid.org/0000-0003-0725-6263","observed_orcids":["https://orcid.org/0000-0003-0725-6263"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth L. McClain","raw_affiliation_strings":["Baylor College of Medicine, Texas Children's Cancer and Hematology Centers  Houston Texas USA"],"raw_orcid":"https://orcid.org/0000-0003-0725-6263","affiliations":[{"raw_affiliation_string":"Baylor College of Medicine, Texas Children's Cancer and Hematology Centers  Houston Texas USA","institution_ids":["https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031416380","display_name":"Oussama Abla","orcid":"https://orcid.org/0000-0001-7446-6274","observed_orcids":["https://orcid.org/0000-0001-7446-6274"]},"institutions":[{"id":"https://openalex.org/I2801317318","display_name":"Hospital for Sick Children","ror":"https://ror.org/057q4rt57","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801317318"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Oussama Abla","raw_affiliation_strings":["Division of Hematology/Oncology, Department of Pediatrics The Hospital for Sick Children  Toronto Ontario Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Department of Pediatrics The Hospital for Sick Children  Toronto Ontario Canada","institution_ids":["https://openalex.org/I2801317318"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015042510","display_name":"David C. Fajgenbaum","orcid":"https://orcid.org/0000-0002-7367-8184","observed_orcids":["https://orcid.org/0000-0002-7367-8184"]},"institutions":[{"id":"https://openalex.org/I4405260438","display_name":"Every Cure","ror":"https://ror.org/03rh5w887","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405260438"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. Fajgenbaum","raw_affiliation_strings":["Division of Translational Medicine & Human Genetics University of Pennsylvania  Philadelphia Pennsylvania USA","Every Cure  Philadelphia Pennsylvania USA"],"raw_orcid":"https://orcid.org/0000-0002-7367-8184","affiliations":[{"raw_affiliation_string":"Division of Translational Medicine & Human Genetics University of Pennsylvania  Philadelphia Pennsylvania USA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"Every Cure  Philadelphia Pennsylvania USA","institution_ids":["https://openalex.org/I4405260438"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062472665","display_name":"Luke Y. C. Chen","orcid":"https://orcid.org/0000-0002-9551-2951","observed_orcids":["https://orcid.org/0000-0002-9551-2951"]},"institutions":[{"id":"https://openalex.org/I129902397","display_name":"Dalhousie University","ror":"https://ror.org/01e6qks80","country_code":"CA","type":"education","lineage":["https://openalex.org/I129902397"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]},{"id":"https://openalex.org/I2802394193","display_name":"Nova Scotia Health Authority","ror":"https://ror.org/035gna214","country_code":"CA","type":"government","lineage":["https://openalex.org/I2802394193"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Luke Y. C. Chen","raw_affiliation_strings":["Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Innovation Hub  Halifax Nova Scotia Canada","Division of Hematology Dalhousie University  Halifax Nova Scotia Canada","Division of Hematology University of British Columbia  Vancouver British Columbia Canada"],"raw_orcid":"https://orcid.org/0000-0002-9551-2951","affiliations":[{"raw_affiliation_string":"Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Innovation Hub  Halifax Nova Scotia Canada","institution_ids":["https://openalex.org/I2802394193"]},{"raw_affiliation_string":"Division of Hematology Dalhousie University  Halifax Nova Scotia Canada","institution_ids":["https://openalex.org/I129902397"]},{"raw_affiliation_string":"Division of Hematology University of British Columbia  Vancouver British Columbia Canada","institution_ids":["https://openalex.org/I141945490"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5062472665"],"corresponding_institution_ids":["https://openalex.org/I129902397","https://openalex.org/I141945490","https://openalex.org/I2802394193"],"apc_list":{"value":5450,"currency":"USD","value_usd":5450},"apc_paid":null,"fwci":12.5137,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.985246,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":97},"biblio":{"volume":"101","issue":"7","first_page":"1478","last_page":"1483"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11909","display_name":"Histiocytic Disorders and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11909","display_name":"Histiocytic Disorders and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10980","display_name":"Vascular Malformations and Hemangiomas","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rosai-dorfman-disease","display_name":"Rosai-Dorfman disease","score":0.9869999885559082},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.8700000047683716},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":1.0},{"id":"https://openalex.org/keywords/refractory-disease","display_name":"refractory disease","score":0.7570000290870667},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.9179999828338623},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.9100000262260437},{"id":"https://openalex.org/keywords/biomedical-knowledge-graphs","display_name":"biomedical knowledge graphs","score":0.8690000176429749},{"id":"https://openalex.org/keywords/mapk-erk-pathway","display_name":"MAPK/ERK pathway","score":0.7749999761581421},{"id":"https://openalex.org/keywords/histiocytic-neoplasms","display_name":"histiocytic neoplasms","score":0.8209999799728394},{"id":"https://openalex.org/keywords/rare-diseases","display_name":"rare diseases","score":0.5849999785423279},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.46399998664855957},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.421999990940094},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.5120000243186951}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8312000036239624},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.7347000241279602},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4984999895095825},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.414000004529953},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.33230000734329224},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3057999908924103},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25049999356269836},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.22370000183582306},{"id":"https://openalex.org/C81182388","wikidata":"https://www.wikidata.org/wiki/Q353963","display_name":"Complication","level":2,"score":0.22130000591278076},{"id":"https://openalex.org/C71472368","wikidata":"https://www.wikidata.org/wiki/Q676880","display_name":"Text mining","level":2,"score":0.20589999854564667}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015618","descriptor_name":"Histiocytosis, Sinus","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/ajh.70309","doi":"https://doi.org/10.1002/ajh.70309","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ajh.70309","pdf_url":null,"source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},{"id":"pmid:41928050","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41928050","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of hematology","raw_type":"Letter"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F2294704616","display_name":"Advanced Research Projects Agency for Health","ror":"https://ror.org/01r532x50"},{"id":"https://openalex.org/F4320315474","display_name":"Chan Zuckerberg Initiative","ror":"https://ror.org/02qenvm24"},{"id":"https://openalex.org/F4320319748","display_name":"Lyda Hill Philanthropies","ror":null},{"id":"https://openalex.org/F4320337338","display_name":"National Heart, Lung, and Blood Institute","ror":"https://ror.org/012pb6c26"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W2015345028","https://openalex.org/W2068412287","https://openalex.org/W2139229231","https://openalex.org/W2802582740","https://openalex.org/W2921153272","https://openalex.org/W2954850764","https://openalex.org/W2968353232","https://openalex.org/W3213265897","https://openalex.org/W4206457078","https://openalex.org/W4220820793","https://openalex.org/W4298005542","https://openalex.org/W4302306958","https://openalex.org/W4399480733","https://openalex.org/W4399882774","https://openalex.org/W4402931643","https://openalex.org/W4413270532"],"related_works":["https://openalex.org/W4389259552","https://openalex.org/W4399882774","https://openalex.org/W2910967165","https://openalex.org/W4386278268","https://openalex.org/W4226325912","https://openalex.org/W4292678304","https://openalex.org/W2139229231","https://openalex.org/W4402931643","https://openalex.org/W4210655746","https://openalex.org/W4226451320"],"abstract_inverted_index":{"A":[0,1223],"combined":[1,307,858],"clinical":[2,308,395,624,724,790,812,981,1001,1310,1488],"and":[3,14,30,34,50,103,107,115,130,152,177,196,220,236,269,309,374,403,460,472,474,511,535,537,612,728,785,801,825,843,865,872,922,927,936,971,989,993,1002,1047,1055,1061,1074,1112,1152,1177,1194,1204,1233,1252,1260,1270,1287,1290,1340,1344,1353,1406,1433,1452,1457,1545,1549,1575,1585,1599,1610,1664,1688,1737,1741,1746],"computational":[4,426,1304,1494],"pharmacophenomic":[5,310,1495],"study":[6,182,1151,1201,1671,1713],"from":[7,350,379,658,670,743,1021,1522,1560,1582,1718],"the":[8,60,63,92,212,225,246,326,342,351,458,497,509,514,744,749,779,819,831,947,1034,1049,1079,1229,1315,1336,1359,1374,1385,1421,1428,1481,1523,1529,1541,1576,1586,1608,1617,1625,1675,1709,1719,1813,1823,1835,1839],"Coastal":[9,327],"Rare":[10,328,1636,1656,1668],"Inflammatory":[11,329],"Diseases":[12,330],"Program":[13],"Every":[15,1556,1583],"Cure.":[16],"Rosai-Dorfman-Destombes":[17],"(RDD)":[18],"disease":[19,42,160,221,336,414,475,573,733,816,1292],"is":[20,39,202,252,285,818,911,1131,1242,1516,1538,1780,1809],"a":[21,133,178,306,319,333,383,425,454,492,502,551,629,633,878,1027,1266,1319,1502,1519,1768],"rare":[22,289,335],"histiocytic":[23,73],"neoplasm":[24],"that":[25,121,210,949,1450,1707],"commonly":[26,1325],"presents":[27],"with":[28,81,194,231,276,362,367,382,506,550,628,684,704,852,859,863,953,964,1068,1078,1133,1183,1492,1744,1799],"skin":[29],"subcutaneous":[31],"masses,":[32],"lymphadenopathy,":[33],"bone":[35],"lesions":[36],"[1].":[37],"Management":[38],"guided":[40],"by":[41,260,339,394,913,1518,1540,1580,1674,1822],"extent,":[43],"symptom":[44],"burden,":[45],"presence":[46],"of":[47,62,79,112,165,188,215,228,245,271,312,322,341,353,386,501,527,556,563,655,678,688,746,751,850,946,1036,1045,1083,1136,1175,1210,1225,1231,1247,1275,1330,1363,1431,1483,1607,1624,1677,1703,1711,1760,1793,1801,1817],"targetable":[48,84,1468],"mutations,":[49],"treatment":[51,714,736,873,1192,1301,1505,1743],"response":[52,186,391,419,635,984,1118],"[1,":[53,161],"2].":[54],"Although":[55,1024],"recent":[56,179],"studies":[57],"have":[58,895,903,1195,1265,1471],"highlighted":[59],"role":[61],"mitogen-activated":[64],"protein":[65],"kinases-extracellular":[66],"signal-regulated":[67],"kinases":[68],"(MAPK\u2013ERK)":[69],"pathway":[70,890,1186],"mutations":[71,85,595,891,975,1469],"in":[72,158,167,172,190,288,314,325,430,567,576,585,682,776,789,811,814,882,906,933,996,999,1039,1139,1149,1207,1236,1296,1370,1411,1415,1460,1464,1602],"disorders":[74],"[3,":[75],"4],":[76],"approximately":[77,232],"60%":[78,1246],"patients":[80,192,323,361,543,578,600,650,722,851,886,1211,1249,1465],"RDD":[82,122,168,365,1248],"lack":[83,1467],"on":[86,416,447,695,713,735,976,1379,1716],"next":[87],"generation":[88],"sequencing":[89],"(NGS),":[90],"underscoring":[91],"need":[93],"for":[94,206,421,439,483,504,676,773,885,1179,1347,1507,1566,1591,1692,1812,1838],"alternative":[95],"therapeutic":[96,136,213,880,1361],"strategies.":[97],"Immunomodulatory":[98],"drugs":[99,235,772],"(IMiDs),":[100],"including":[101,266,525,841,1299,1463],"thalidomide":[102],"lenalidomide,":[104],"exert":[105],"anti-inflammatory":[106],"antineoplastic":[108],"effects":[109],"through":[110,1528],"modulation":[111],"cytokine":[113],"signaling":[114,1394],"cereblon-mediated":[116],"pathways":[117],"[5,":[118],"6].":[119],"Given":[120,224],"pathophysiology":[123],"involves":[124],"cytokine-driven":[125],"inflammation\u2014including":[126],"tumor":[127],"necrosis":[128],"factor":[129],"interleukin-6\u2014lenalidomide":[131],"represents":[132],"biologically":[134],"rational":[135],"candidate.":[137],"The":[138,710,739,1173,1475,1561,1597,1698,1705,1722,1807],"National":[139,1542],"Cancer":[140],"Care":[141],"Network":[142,466],"(NCCN)":[143],"guidelines":[144],"list":[145],"lenalidomide":[146,195,802,810,828,857,926,1046,1259,1451,1745],"as":[147,292,405,603,617,830,1390,1392,1397,1408,1501,1615],"an":[148,184,203,1010,1380],"\u201cother":[149],"recommended":[150,1342],"regimen,\u201d":[151],"expert":[153],"consensus":[154,418],"supports":[155,1308],"its":[156,1412],"use":[157,1035,1230],"refractory":[159,855],"7].":[162],"Clinical":[163,356,1680,1736],"activity":[164,775],"IMiDs":[166,1084],"has":[169],"been":[170],"described":[171],"numerous":[173],"case":[174],"reports":[175],"[8-10],":[176],"phase":[180],"II":[181],"demonstrated":[183,723],"overall":[185,797],"rate":[187],"87%":[189],"23":[191],"treated":[193,366],"dexamethasone":[197,685,860,994,1062,1261,1453],"(len/dex)":[198],"[11].":[199],"Computational":[200,766],"pharmacophenomics":[201,427,767,1305],"emerging":[204],"approach":[205,259,284,428],"systemic":[207,607,898,1327],"drug":[208,436,473,503,539,920],"repurposing":[209,437],"evaluates":[211],"potential":[214,1178],"approved":[216,1673],"agents":[217,784],"across":[218,596,653,869,1284],"diseases":[219,290],"subtypes":[222,871],"[12].":[223],"vast":[226],"amount":[227],"data":[229,264,376,384,752,1706,1723],"available:":[230],"4000":[233],"FDA-approved":[234,771],"18":[237],"500":[238],"recognized":[239],"human":[240],"diseases,":[241],"manual":[242],"identification":[243],"alone":[244],"75":[247],"000":[248,249],"possible":[250],"combinations":[251],"impossible.":[253],"Biomedical":[254],"knowledge":[255,462,1443],"graphs":[256,463],"enable":[257],"this":[258,302,815,848,954,1150,1313,1484,1603,1693,1712],"integrating":[261,457],"diverse":[262],"biomedical":[263,455],"sources,":[265],"drug\u2013disease":[267,449,484],"associations":[268],"mechanisms":[270],"action,":[272],"to":[273,434,453,479,490,521,636,645,660,672,690,748,917,985,1091,1119,1126,1165,1217,1427,1438,1686,1729,1834],"identify":[274],"therapies":[275,1254,1346],"shared":[277],"biological":[278,499],"or":[279,401,412,619,708,854,892,982,1220,1470,1509,1622,1731,1815],"pathophysiologic":[280],"features":[281],"[13].":[282],"This":[283,1356,1670],"particularly":[286,884],"valuable":[287],"such":[291,616,1396],"RDD,":[293,505,856,883,1208,1462],"where":[294],"conventional":[295,897],"large-scale":[296],"trials":[297],"are":[298,929,944,1250,1255,1262,1367,1490,1605,1714,1724],"often":[299,808,1189],"infeasible.":[300],"In":[301,847,924,1199,1257,1278],"study,":[303],"we":[304,317],"conducted":[305,318],"analysis":[311,768,1306],"len/dex":[313,368,652,1120,1176],"RDD.":[315,440,777,1511],"First,":[316],"retrospective":[320,1696],"review":[321],"enrolled":[324],"(CoRID)":[331],"program,":[332],"Canadian":[334],"program":[337],"directed":[338,1833],"one":[340,589,730,1200],"senior":[343],"authors":[344,1609,1699],"(LC).":[345],"Ethics":[346,358,1682],"approval":[347],"was":[348,392,432,451,574,583,665,715,754,861,1051,1294,1672,1690],"obtained":[349],"University":[352,1676],"British":[354,1678],"Columbia":[355,1679],"Research":[357,1563,1588,1662,1681],"Board.":[359],"Eleven":[360,542],"histopathologically":[363],"confirmed":[364],"were":[369,377,468,477,488,517,544,565,782,1063,1076,1089,1096,1147,1158,1282],"included.":[370],"Demographic,":[371],"clinical,":[372],"radiographic,":[373],"outcome":[375],"abstracted":[378],"medical":[380,529],"records,":[381],"cutoff":[385],"October":[387],"31,":[388],"2025.":[389],"Treatment":[390],"assessed":[393],"evaluation":[396],"and/or":[397,725],"imaging":[398],"(PET-CT,":[399],"CT,":[400],"MRI)":[402],"categorized":[404],"complete":[406,1171],"response,":[407,409],"partial":[408,634],"stable":[410],"disease,":[411,908,1372],"progressive":[413,732],"based":[415,694],"adapted":[417],"criteria":[420],"histiocytoses":[422],"[14].":[423],"Second,":[424],"(manuscript":[429],"preparation)":[431],"used":[433,478,788,1326],"evaluate":[435],"opportunities":[438],"An":[441,956],"ensemble":[442],"machine":[443],"learning":[444],"model":[445,1375,1386],"trained":[446],"known":[448,1080],"relationships":[450],"applied":[452],"network":[456,1440],"RTX-KG2":[459],"ROBOKOP":[461],"[15,":[464],"16].":[465],"nodes":[467],"embedded":[469],"using":[470],"Node2Vec,":[471],"embeddings":[476],"generate":[480],"prediction":[481,1413],"scores":[482,1351,1378],"pairs.":[485],"Model":[486],"outputs":[487],"normalized":[489],"produce":[491,1455],"\u2018treat":[493],"score\u2019":[494],"(0\u20131),":[495],"reflecting":[496],"predicted":[498,774],"plausibility":[500],"0.00":[507],"being":[508,513],"lowest":[510],"0.99":[512],"highest.":[515],"Results":[516],"then":[518,1122],"re-ranked":[519],"according":[520],"various":[522],"strategic":[523],"criteria,":[524],"consideration":[526],"unmet":[528],"need,":[530],"existing":[531],"evidence":[532],"(both":[533],"preclinical":[534],"clinical),":[536],"relevant":[538,1409],"safety":[540,1081,1268],"information.":[541],"included":[545,566],"(six":[546],"males,":[547],"five":[548],"females),":[549],"median":[552,711,740],"age":[553],"at":[554,667,686,698],"diagnosis":[555,747],"55":[557],"years":[558],"(range":[559,718,757],"17\u201380":[560],"years),":[561],"six":[562],"whom":[564],"previous":[568],"publications":[569],"[2,":[570],"17-19].":[571],"Extranodal":[572],"present":[575],"ten":[577],"(Table":[579,662],"I).":[580],"Tissue":[581],"NGS":[582,1240],"performed":[584],"seven":[586],"cases,":[587,1289],"identifying":[588],"KRAS":[590,630,760,1205,1234,1407],"p.K117N":[591,761],"mutation":[592,631,914,1332],"three":[593],"MAP2K1":[594,1028],"two":[597],"patients.":[598],"Five":[599],"received":[601,651,1318,1420],"corticosteroids":[602,786,824,928],"first-line":[604],"therapy.":[605],"Additional":[606],"agents\u2014including":[608],"rituximab,":[609,986],"sirolimus,":[610,987],"cladribine,":[611,988],"methotrexate\u2014and":[613],"local":[614,990],"interventions":[615],"surgery":[618],"radiation":[620],"did":[621],"not":[622,938,1243,1612,1725,1810],"provide":[623],"response.":[625],"One":[626,1102,1160],"patient":[627,1103,1161],"achieved":[632,1295],"trametinib":[637],"but":[638,1121],"discontinued":[639,1162],"therapy":[640,656,1038,1163,1181,1500],"after":[641,1169,1300,1742],"6":[642],"months":[643,717,756,1044],"due":[644,1164,1728],"cutaneous":[646],"toxicity.":[647,923],"All":[648],"eleven":[649],"lines":[654],"ranging":[657,669],"first":[659,1040],"fifth":[661],"1).":[663,738],"Lenalidomide":[664,992,1060,1130],"administered":[666],"doses":[668,687,697],"10":[671],"25":[673],"mg":[674,692],"daily":[675],"21":[677],"every":[679],"28":[680],"days,":[681],"combination":[683,1317],"8":[689,1008],"40":[691],"weekly":[693],"standard":[696],"our":[699,1279,1447],"cancer":[700],"center":[701],"[https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lymphoma-Myeloma/MYLDREL_Protocol.pdf],":[702],"along":[703],"low":[705],"dose":[706,1100,1218],"aspirin":[707],"anticoagulation.":[709],"time":[712,742],"18.1":[716],"4.0\u201359.2":[719],"months).":[720,759],"Ten":[721],"radiographic":[726,1003,1738],"benefit,":[727],"only":[729,1069],"experienced":[731],"while":[734],"(Figure":[737,792,845,1005,1058],"follow-up":[741],"date":[745,750],"cut-off":[753],"33.1":[755],"11.0\u201378.7":[758],"FUBP1":[762],"p.I443V":[763],"ERBB4":[764],"p.V949I":[765],"evaluated":[769],"2975":[770],"Among":[778],"highest-ranked":[780],"candidates":[781],"cytotoxic":[783,839],"currently":[787],"practice":[791,813],"2A,C).":[793],"Dexamethasone":[794],"ranked":[795,803,833],"4th":[796],"(treat":[798],"score":[799,1322],"0.9986),":[800],"23rd":[804],"(0.9967).":[805],"Dexamethasone,":[806],"which":[807,1095,1188,1366],"accompanies":[809],"space,":[817],"highest-rated":[820],"corticosteroid.":[821],"When":[822],"excluding":[823],"traditional":[826],"chemotherapies,":[827],"emerged":[829],"third-highest":[832],"agent,":[834],"exceeding":[835],"several":[836,1297],"NCCN":[837],"\u201cpreferred\u201d":[838],"therapies,":[840,1328],"cladribine":[842],"cytarabine":[844],"2B).":[846],"series":[849],"relapsed":[853],"associated":[862,1132],"consistent":[864,1077,1491],"clinically":[866],"meaningful":[867,1456],"benefit":[868],"molecular":[870,918],"lines.":[874],"These":[875],"findings":[876,1448,1710],"address":[877],"key":[879],"gap":[881],"without":[887,1098],"actionable":[888,974],"MAPK\u2013ERK":[889],"those":[893,1606],"who":[894,1466],"exhausted":[896,1472],"options.":[899],"While":[900],"targeted":[901,1037,1184,1253],"inhibitors":[902,1206,1235,1338],"transformed":[904],"management":[905],"mutation-positive":[907,1286,1371],"their":[909],"utility":[910],"limited":[912,1090],"prevalence,":[915],"access":[916],"testing,":[919],"availability,":[921],"contrast,":[925,1258],"broadly":[930],"accessible":[931,1504],"even":[932,1335],"lower-income":[934],"countries,":[935],"do":[937],"require":[939,1190],"genomic":[940],"stratification.":[941],"Some":[942],"cases":[943],"illustrative":[945],"responses":[948,1281,1459,1739],"can":[950,1271,1454],"be":[951,1272,1613,1832],"seen":[952],"regimen.":[955,1485],"80":[957],"year":[958],"old":[959],"man":[960],"(case":[961,1104],"3)":[962],"presented":[963],"large":[965],"peri-orbital":[966],"masses":[967],"affecting":[968],"his":[969],"vision":[970],"had":[972,979,1009,1026,1106,1116],"no":[973,1052,1143,1153,1701],"NGS.":[977],"He":[978,1115],"minimal":[980,1694],"radiological":[983],"radiation.":[991],"given":[995],"fifth-line":[997],"resulted":[998],"substantial":[1000],"improvement":[1004],"S1C,D).":[1006],"Case":[1007,1749,1756,1766,1789],"8.6":[1011],"cm":[1012,1774],"right":[1013,1751,1761,1775,1784,1802],"thigh":[1014,1752,1762],"soft":[1015],"tissue":[1016],"lesion":[1017],"causing":[1018,1782],"significant":[1019,1196],"discomfort":[1020],"femoroacetabular":[1022],"impingement.":[1023],"she":[1025],"mutation,":[1029],"medication":[1030],"coverage":[1031,1436],"issues":[1032],"precluded":[1033],"line.":[1041],"After":[1042],"7":[1043],"dexamethasone,":[1048],"mass":[1050,1753,1763,1777,1795],"longer":[1053],"palpable":[1054],"symptoms":[1056],"resolved":[1057],"S1A,B).":[1059],"also":[1064],"generally":[1065],"well":[1066,1391],"tolerated,":[1067],"low-grade":[1070],"adverse":[1071,1087,1156,1214],"events":[1072,1088,1157,1215],"observed":[1073,1148,1283],"toxicities":[1075,1478],"profile":[1082],"[7].":[1085],"Most":[1086],"grade":[1092,1166],"1":[1093,1167],"toxicities,":[1094],"manageable":[1097,1477],"routine":[1099],"modification.":[1101],"11)":[1105],"composite":[1107],"marginal":[1108],"zone":[1109],"lymphoma/RDD,":[1110],"frailty,":[1111],"multiple":[1113,1473],"comorbidities.":[1114],"initial":[1117],"developed":[1123,1212],"fatal":[1124],"transformation":[1125],"aggressive":[1127],"B-cell":[1128],"lymphoma.":[1129],"increased":[1134],"risk":[1135,1695],"secondary":[1137,1145],"malignancies":[1138,1146],"myeloma":[1140],"cohorts":[1141],"[20];":[1142],"other":[1144,1154,1324],"hematological":[1155],"observed.":[1159],"transaminitis":[1168],"achieving":[1170],"remission.":[1172],"tolerability":[1174,1197],"time-limited":[1180],"contrast":[1182],"MAPK":[1185,1331],"inhibitors,":[1187,1365],"indefinite":[1191],"duration":[1193],"issues.":[1198],"evaluating":[1202],"MEK":[1203,1232,1337,1364,1389],"56%":[1209],"treatment-related":[1213],"leading":[1216,1437],"reduction":[1219],"discontinuation":[1221],"[4].":[1222],"number":[1224,1595],"practical":[1226],"considerations":[1227],"limit":[1228],"lower":[1237,1350],"income":[1238],"jurisdictions:":[1239],"testing":[1241],"universally":[1244],"available,":[1245],"wild-type,":[1251],"costly.":[1256],"widely":[1263],"accessible,":[1264],"well-established":[1267],"profile,":[1269],"effective":[1273,1368],"irrespective":[1274,1329],"mutational":[1276],"status.":[1277,1333],"cohort,":[1280],"both":[1285],"wild-type":[1288,1510],"durable":[1291,1458],"control":[1293],"patients,":[1298],"discontinuation.":[1302],"Our":[1303],"further":[1307,1479],"these":[1309,1417,1487],"observations.":[1311],"Within":[1312],"framework,":[1314],"lenalidomide/dexamethasone":[1316],"higher":[1320],"probability":[1321,1377,1423],"than":[1323,1828],"Notably,":[1334],"cobimetinib":[1339],"trametinib\u2014the":[1341],"first-":[1343],"second-line":[1345],"MAPK-mutant":[1348],"RDD\u2014received":[1349],"(0.84":[1352],"0.80,":[1354],"respectively).":[1355],"likely":[1357,1425],"reflects":[1358],"narrower":[1360],"context":[1362],"primarily":[1369],"whereas":[1373],"assigns":[1376],"all-comers,":[1381],"mutation-agnostic":[1382],"basis.":[1383],"Importantly,":[1384,1486],"appropriately":[1387],"identifies":[1388],"upstream":[1393],"genes":[1395],"V-Raf":[1398],"Murine":[1399],"Sarcoma":[1400],"Viral":[1401],"Oncogene":[1402],"Homolog":[1403],"B":[1404],"(BRAF)":[1405],"entities":[1410],"process":[1414],"making":[1416],"determinations.":[1418],"Rituximab":[1419],"highest":[1422],"score,":[1424],"owing":[1426],"well-characterized":[1429],"mechanism":[1430],"action":[1432],"extensive":[1434],"literature":[1435],"stronger":[1439],"connectivity":[1441],"within":[1442],"graphs.":[1444],"Taken":[1445],"together,":[1446],"demonstrate":[1449],"relapsed/refractory":[1461],"therapies.":[1474],"low-grade,":[1476],"support":[1480,1708],"practicality":[1482],"outcomes":[1489],"favorable":[1493],"predictions,":[1496],"collectively":[1497],"suggesting":[1498],"lenalidomide-based":[1499],"promising,":[1503],"option":[1506],"refractory/relapsed":[1508],"Luke":[1512,1629],"Y.C.":[1513,1630],"Chen's":[1514],"research":[1515,1537],"supported":[1517,1539],"philanthropic":[1520],"gift":[1521],"Hsu":[1524],"&":[1525,1531,1552],"Taylor":[1526],"Family":[1527],"UBC":[1530],"VGH":[1532],"Foundation.":[1533],"David":[1534,1659],"C.":[1535,1660,1765],"Fajgenbaum's":[1536],"Heart,":[1543],"Lung,":[1544],"Blood":[1546],"Institute":[1547],"(R01HL141408)":[1548],"US":[1550],"Food":[1551],"Drug":[1553],"Administration":[1554],"(R01FD007632).":[1555],"Cure":[1557,1584],"receives":[1558],"funding":[1559,1581],"Advanced":[1562,1587],"Projects":[1564,1589],"Agency":[1565,1590],"Health":[1567,1592],"(ARPA-H),":[1568],"Chan":[1569],"Zuckerberg":[1570],"Initiative,":[1571],"Lyda":[1572],"Hill":[1573],"Philanthropies,":[1574],"Audacious":[1577],"Project.":[1578],"Supported":[1579],"(ARPA-H,":[1593],"agreement":[1594],"140D042490001).":[1596],"views":[1598],"conclusions":[1600],"contained":[1601],"document":[1604],"should":[1611,1831],"interpreted":[1614],"representing":[1616],"official":[1618],"policies,":[1619],"either":[1620],"expressed":[1621],"implied,":[1623],"United":[1626],"States":[1627],"Government.":[1628],"Chen:":[1631],"Honoraria":[1632,1641,1649],"\u2013":[1633,1642,1650,1666],"Glaxo-Smith-Kline,":[1634],"Recordati":[1635,1655,1667],"Diseases.":[1637,1669],"Rebecca":[1638],"A.":[1639,1748],"Harrison:":[1640],"Servier":[1643],"Canada,":[1644],"Novocure":[1645],"Canada.":[1646],"Julia":[1647],"Varghese:":[1648],"Janssen,":[1651],"Pfizer,":[1652],"GSK,":[1653],"FORUS,":[1654],"Diseases,":[1657],"Sanofi.":[1658],"Fajgenbaum:":[1661],"Funding":[1663],"Consulting":[1665],"Board;":[1683],"individual":[1684],"consent":[1685,1689],"participate":[1687],"waived":[1691],"study.":[1697],"declare":[1700],"conflicts":[1702],"interest.":[1704],"available":[1715,1727],"request":[1717],"corresponding":[1720,1836],"author.":[1721],"publicly":[1726],"privacy":[1730],"ethical":[1732],"restrictions.":[1733],"Figure":[1734],"S1:":[1735],"before":[1740],"dexamethasone.":[1747],"8,":[1750,1757],"pre-treatment.":[1754,1787],"B.":[1755],"near":[1758,1791],"resolution":[1759,1792,1800],"post-treatment.":[1764],"3,":[1767,1790],"3.0":[1769],"\u00d7":[1770,1772],"2.9":[1771],"1.6":[1773],"orbital":[1776,1794],"(red":[1778,1796],"arrow)":[1779,1797],"shown":[1781],"severe":[1783],"eye":[1785,1803],"ptosis":[1786],"D.":[1788],"post-treatment":[1798],"ptosis.":[1804],"Please":[1805],"note:":[1806],"publisher":[1808],"responsible":[1811],"content":[1814],"functionality":[1816],"any":[1818],"supporting":[1819],"information":[1820],"supplied":[1821],"authors.":[1824],"Any":[1825],"queries":[1826],"(other":[1827],"missing":[1829],"content)":[1830],"author":[1837],"article.":[1840]},"counts_by_year":[{"year":2026,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-04-03T00:00:00"}